Sign in Subscribe

Veracyte Buys Convergent Genomics for Up to $180 Million, Adding a Urine Test for Bladder Cancer

Veracyte acquired Convergent Genomics for $150M cash plus up to $30M in milestones, adding UroAmp, a urine tumor DNA test for bladder cancer.

Veracyte Buys Convergent Genomics for Up to $180 Million, Adding a Urine Test for Bladder Cancer
convergentgenomics.com/
Already have an account? Sign in.